Frequency has found a partner in Astellas for its regenerative therapy to treat hearing loss in a deal that will support development of FX-322 as it moves into Phase IIa testing next quarter.
Astellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the patient experience.
Pfizer and Astellas’ Xtandi is gunning for a new indication in prostate cancer, and they argue today's new data—showing the med cut the risk of death by a third—complement the evidence they’ve already generated.
Astellas and Amgen agreed to pay nearly $125 million to settle a Justice Department investigation into their relationships with charities—and allegations that they used donations as kickbacks to pump up prescriptions.
Clinical-stage biopharmaceutical firm Xencor has entered into a research collaboration with Astellas Pharma for novel bispecific antibody program.
Astellas is looking to snap up share with Xospata before a head-to-head rival hits the acute myeloid leukemia scene, and some new survival data could help speed that process along.
Seattle Genetics is one step closer to getting its second armed antibody across the finish line, after the ‘breakthrough’ Astellas-partnered drug — enfortumab vedotin — helped patients with advanced or metastatic urothelial cancer, whose disease progressed despite treatment with both platinum-containing chemotherapy and a checkpoint inhibitor, in a key study.
Bayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the pressure on rivals Johnson & Johnson and Pfizer/Astellas.
When it comes to using Xtandi in hormone-sensitive prostate cancer, Pfizer and Astellas are “really excited,” executives have said. And new data shows the partners have reason to be.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone.